Evidence map›Paper›PMID 39725619›Full record

ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2024

[High expression of AURKB promotes malignant phenotype of osteosarcoma cells by activating nuclear factor-κB signaling

Yanxin Zhong, Yu Liu, Weilai Tong, Xinsheng Xie, Jiangbo Nie, Feng Yang, Zhili Liu, Jiaming Liu

Abstract readEnglish Abstract
In one paragraph

Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yanxin ZhongDepartment of Orthopedics, Nanchang 330006, China.
Yu LiuDepartment of Orthopedics, Nanchang 330006, China.
Weilai TongDepartment of Orthopedics, Nanchang 330006, China.
Xinsheng XieMedical Research Public Service Center, First Affiliated Hospital of Nanchang University, Nanchang 330006, China, Nanchang 330006, China.
Jiangbo NieDepartment of Orthopedics, Nanchang 330006, China.
Feng YangDepartment of Orthopedics, Nanchang 330006, China.
Zhili LiuDepartment of Orthopedics, Nanchang 330006, China.
Jiaming LiuDepartment of Orthopedics, Nanchang 330006, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo investigate the regulatory mechanism of aurora kinase B (AURKB) for promoting malignant phenotype of osteosarcoma cells.

methodsHA-Vector or HA-AURKB was transfected in 293T cells to identify the molecules interacting with AURKB using immunoprecipitation combined with liquid chromatography-tandem mass spectrometry followed by verification with co-immunoprecipitation and Western blotting. In cultured osteosarcoma cells with lentivirus-mediated RNA interference of AURKB or DHX9 or their overexpression, the changes in cell proliferation, migration, and invasion activities were observed with EDU and Transwell assays. Mechanistic analysis was performed using Co-IP and

resultsAURKB was highly expressed in osteosarcoma cell lines, and in osteosarcoma 143B cells, AURKB silencing significantly reduced cell proliferation, migration and invasion abilities. Interactions between AURKB and DHX9 were detected, and they were both highly expressed in osteosarcoma tissues; silencing AURKB reduced the protein expression of DHX9, and AURKB overexpression increased DHX9 phosphorylation. Silencing AURKB did not significantly affect the transcription and translation of DHX9 but accelerated its degradation and ubiquitination. Overexpression of DHX9 effectively reversed the effects of AURKB silencing on IKBα protein and phosphorylated p65, promoted nuclear translocation of p65 to activate the NF-κB signaling pathway, and enhanced the proliferation, migration, and invasion abilities of cultured osteosarcoma cells.

conclusionsAURKB overexpression promotes the malignant phenotype of osteosarcoma cells by activating the NF-κB signaling pathway via regulating DHX9.

Indexed as

Aurora Kinase BCell MovementCell ProliferationDEAD-box RNA HelicasesNF-kappa BOsteosarcomaSignal TransductionBone NeoplasmsCell Line, TumorHumansNeoplasm InvasivenessNeoplasm ProteinsPhenotypePhosphorylationAURKB protein, humanAurora Kinase BDEAD-box RNA HelicasesDHX9 protein, humanNeoplasm ProteinsNF-kappa Baurora kinase BDHX9osteosarcomaphosphorylation

Identifiers

PMID39725619
PMCPMC11683349

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.